|
Variable
|
Relapse
|
NRM
|
DFS
|
OS
|
|---|
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
Univariate
|
Multivariate
|
|---|
| |
P
| |
P
| |
P
| |
P
|
|---|
| |
HR (95% CI)
| |
HR (95% CI)
| |
HR (95% CI)
| |
HR (95% CI)
|
|---|
|
Age
|
0.988
|
–
|
0.169
|
–
|
0.21
|
–
|
0.21
|
–
|
| |
1.00 (0.96–1.04)
| |
1.02 (0.99–1.05)
| |
1.02 (0.99–1.04)
| |
1.02 (0.99–1.04)
| |
|
Sex
| |
–
| |
–
| |
–
| |
–
|
|
Male
|
Ref.
| |
Ref.
| |
Ref.
| |
Ref.
| |
|
Female
|
0.566
| |
0.304
| |
0.245
| |
0.319
| |
| |
0.76 (0.30–1.93)
| |
0.70 (0.36–1.38)
| |
0.72 (0.42–1.25)
| |
0.74 (0.41–1.34)
| |
|
Cytogenetics
| | | | | | | | |
|
Non–complex karyotypes
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
|
Complex karyotypes
|
0.012
|
0.006
|
0.328
|
0.347
|
0.012
|
0.020
|
0.014
|
0.009
|
| |
3.51 (1.32–9.34)
|
4.16 (1.51–11.45)
|
1.51 (0.66–3.46)
|
1.51 (0.64–3.55)
|
2.24 (1.19–4.20)
|
2.16 (1.13–4.12)
|
2.28 (1.18–4.42)
|
2.47 (1.25–4.90)
|
|
BM blasts at HSCT
| | | | | | | | |
|
≤ 5%
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
|
> 5%
|
0.349
|
0.253
|
0.343
|
0.245
|
0.782
|
0.773
|
0.763
|
0.73
|
| |
1.80 (0.53–6.20)
|
2.08 (0.59–7.31)
|
0.72 (0.36–1.43)
|
0.66 (0.33–1.33)
|
0.92 (0.51–1.66)
|
0.92 (0.51–1.66)
|
0.91 (0.48–1.72)
|
0.89 (0.47–1.69)
|
|
Myelofibrosis
| | | | | | | | |
|
MF = 0/1
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
|
MF = 2/3
|
0.964
|
0.914
|
0.986
|
0.286
|
0.459
|
0.396
|
0.569
|
0.444
|
| |
0.97 (0.28–3.34)
|
1.07 (0.31–3.76)
|
1.02 (0.13–8.15)
|
0.56 (0.20–1.62)
|
0.74 (0.34–1.64)
|
0.71 (0.32–1.58)
|
0.78 (0.33–1.84)
|
0.71 (0.30–1.70)
|
|
Time to HSCT from diagnosis
|
|
≤ 6 months
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
|
> 6 months
|
0.77
|
0.888
|
0.56
|
0.709
|
0.952
|
0.678
|
0.741
|
0.526
|
| |
0.86 (0.31–2.39)
|
1.08 (0.38–3.08)
|
0.63 (0.13–3.02)
|
1.15 (0.56–2.34)
|
1.02 (0.58–1.80)
|
1.13 (0.63–2.04)
|
1.11 (0.60–2.04)
|
1.23 (0.65–2.31)
|
|
Previous therapy for MDS
|
|
No cytoreductive treatments
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
Ref.
|
|
Cytoreductive treatments
|
0.468
|
0.327
|
0.337
|
0.642
|
0.902
|
0.856
|
0.794
|
0.627
|
| |
1.41 (0.56–3.60)
|
1.61 (0.62–4.19)
|
1.97 (0.49–7.89)
|
0.86 (0.45–1.64)
|
0.97 (0.57–1.63)
|
1.05 (0.62–1.79)
|
1.08 (0.61–1.91)
|
1.16 (0.64–2.07)
|
|
Donor source
|
|
HID
|
Ref
|
–
|
Ref
|
–
|
Ref
|
–
|
Ref
|
–
|
|
MUD
|
0.806
| |
0.277
| |
0.709
| |
0.903
| |
| |
0.77 (0.09–6.50)
| |
2.49 (0.48–12.81)
| |
0.82 (0.28–2.37)
| |
1.07 (0.37–3.13)
| |
|
MSD
|
0.393
| |
0.374
| |
0.646
| |
0.717
| |
| |
1.54 (0.57–4.11)
| |
0.48 (0.09–2.45)
| |
0.88 (0.51–1.51)
| |
0.90 (0.50–1.62)
| |
|
Stem cell source
|
|
PB
|
Ref
|
–
|
Ref
|
–
|
Ref
|
–
|
Ref
|
–
|
|
PB + BM
|
0.325
| |
0.628
| |
0.899
| |
0.666
| |
| |
1.60 (0.63–4.07)
| |
0.85 (0.45–1.62)
| |
1.03 (0.61–1.74)
| |
1.13 (0.64–2.00)
| |
- NRM non-replase mortality, RI relapse incidence, DFS disease-free survival, OS overall survival (after allo-HSCT), MF myelofibrosis
